Page last updated: 2024-12-11
bms561392
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BMS561392: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9847838 |
| CHEMBL ID | 489100 |
| SCHEMBL ID | 6350418 |
| MeSH ID | M0453389 |
Synonyms (17)
| Synonym |
|---|
| bdbm50247606 |
| (r)-2-((r)-3-amino-3-(4-((2-methylquinolin-4-yl)methoxy)phenyl)-2-oxopyrrolidin-1-yl)-n-hydroxy-4-methylpentanamide |
| CHEMBL489100 , |
| bms-561392 |
| dpc-333 |
| bms 561392 |
| (2r)-2-[(3r)-3-amino-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]-n-hydroxy-4-methylpentanamide |
| gtpl6509 |
| bms561392 |
| SCHEMBL6350418 |
| dpc 333 |
| unii-2x066a8676 |
| 2X066A8676 , |
| (2r)-2-((3r)-3-amino-3-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)-2-oxo-1-pyrrolidinyl)-n-hydroxy-4-methylpentanamide |
| 611227-74-8 |
| Q27075352 |
| AKOS040750869 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "6 l/kg, an oral bioavailability of 17%, and an ex vivo IC(50) for the suppression of TNF-alpha production of 55 nM (n = 1)." | ( Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in ro Bai, SA; Brogdon, B; Christ, DD; Covington, MB; Decicco, CP; Deng, Y; Duan, JJ; Fossler, MJ; Garner, CE; Liu, RQ; Maduskuie, T; Newton, RC; Qian, M; Trzaskos, J; Vaddi, K; Wu, JT, 2007) | 0.34 |
| " Since the discovery of anti-TNF-alpha biologicals, much efforts have gone into developing an orally bioavailable small size TNF-alpha antagonist." | ( Current perspective of TACE inhibitors: a review. DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR, 2009) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | IC50 (µMol) | 0.0002 | 0.0002 | 1.0140 | 10.0000 | AID347023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (39)
Molecular Functions (14)
Ceullar Components (13)
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID347023 | Inhibition of TACE | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID347195 | Oral bioavailability in rat | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID347019 | Inhibition of LPS-induced TNFalpha production in po dosed mouse | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID347197 | Half life in human | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID347193 | Inhibition of TNFalpha production in whole blood | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID347036 | Oral bioavailability in dog | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| AID1345458 | Human ADAM17 (M12: Astacin/Adamalysin) | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Current perspective of TACE inhibitors: a review. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.93) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 2 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (70.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||